Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation

Epigenomics

Volumn 1, Issue 1, 2009, Pages 201-211

  Dong, Erbo ^a   Grayson, Dennis R ^a   Guidotti, Alessandro ^a   Costa, Erminio ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Antipsychotics; Demethylation; GAD67; Neuroepigenetics; Promoters; Psychosis; Reelin

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; DNA (CYTOSINE 5) METHYLTRANSFERASE; GLUTAMATE DECARBOXYLASE; NERVE CELL ADHESION MOLECULE; NERVE PROTEIN; NEUROLEPTIC AGENT; REELIN PROTEIN; SCLEROPROTEIN; SERINE PROTEINASE;

ANIMAL; ARTICLE; BIPOLAR DISORDER; BRAIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; DOWN REGULATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOUSE; PROMOTER REGION; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAIN; CELL ADHESION MOLECULES, NEURONAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOWN-REGULATION; EXTRACELLULAR MATRIX PROTEINS; GABAERGIC NEURONS; GLUTAMATE DECARBOXYLASE; HUMANS; MICE; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC; SCHIZOPHRENIA; SERINE ENDOPEPTIDASES;

EID: 79959666235     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.09.2     Document Type: Article

References (61)

1. Lieberman JA, Bymaster FP, Meltzer HY et al.: Antipsychotic drugs, comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol. Rev. 60(3), 358-403 (2008).
2. Hyman S: A glimmer of light for neuropsychiatric disorders. Nature 455(16), 890-893 (2008).
3. Costa E, Dong E, Grayson DR et al.: Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics. 2(1), 29-36 (2007). (Pubitemid 46824847)
4. Akbarian S, Kim J J, Potkin SG et al.: Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 52(4), 258-266 (1995).
5. Benes J, Vincent SL, Alsterberger G et al.: Increased GABAergic receptor binding in superficial layers of cingulate cortex in schizophrenia. J. Neurosci. 12, 924-929 (1992).
6. 67) expression in schizophrenia and bipolar disorder, a postmortem brain study. Arch. Gen. Psychiatry 57, 1061-1069 (2000).
7. Guidotti A. Auta J, Davis JM et al.: GABAergic dysfunction in schizophrenia, new treatment strategies on the horizon. Psychopharmacology (Berl.) 180, 191-205 (2005). (Pubitemid 40909664)
8. Lewis DA, Hashimoto T, Volk DW: Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6, 312-324 (2005). (Pubitemid 40469985)
9. Woo TU, Walsh JP, Benes FM: Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 61, 649-657 (2004). (Pubitemid 38890797)
10. Breese CR, Lee MJ, Adams CE et al.: Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23, 351-364 (2000)
11. Mill J, Tang T, Kaminsky Z et al.; Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am. J. Hum. Genet. 82(3), 696-711 (2008). (Pubitemid 351726115)
12. Mellios N, Huang HS, Baker SP et al.: Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol. Psychiatry 65(12), 1006-1014 (2009).
13. Veldic M, Kadriu B, Maloku E et al.: Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr. Res. 91(1-3), 51-61 (2007).
14. Ruzicka WB, Zhubi A, Veldic M et al.: Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. Mol. Psychiatry 12(4), 385-397 (2007). (Pubitemid 46496836)
15. Lisman JE, Coyle JT, Green RW et al.: Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31(5) 234-242 (2008).
16. Fatemi SH, Earle JA, McMenomy T: Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol. Psychiatry 5(6), 654-663 (2000).
17. Soghomonian JJ, Martin DL: Two isoforms of glutamate decarboxylase, why? Trends Pharmacol. Sci. 19, 500-505 (1998). (Pubitemid 29008539)
18. Gonzalez-Burgos G., Lewis DA: GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr. Bull. 34, 944-961 (2008).
19. DArcangelo G, Miao GG, Chen SC et al.: A protein related to extracellular matrix proteins deleted in the mouse mutant reeler. Nature 374(6524), 719-723 (1995).
20. Costa E, Davis JM, Grayson DR et al.: Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol. Dis. 8, 723-742 (2001). (Pubitemid 33055591)
21. Levenson JM, Qiu S, Weeber EJ: The role of reelin in adult synaptic function and the genetic and epigenetic regulation of the reelin gene. Biochim. Biophys. Acta 1779, 422-431 (2008).
22. Grayson DR, Jia X, Chen Y et al.: Reelin promoter hypermethylation in schizophrenia. Proc. Natl Acad. Sci. USA 102(26), 9341-9346 (2005). (Pubitemid 40923565)
23. Chen Y, Sharma R, Costa RH et al.: On the epigenetic regulation of the human reelin promoter. Nucl. Acids Res. 3, 2930-2939 (2002). (Pubitemid 34778154)
24. Van Emburgh B.O., Robertson KD: DNA methyltransferases and methyl CpG binding proteins as multifunctional regulators of chromatin structure and development in mammalian cells. In: Epigenetics. Tost J (Ed.), Caister Academic Press, Norwich, UK, 23-62 (2008).
25. Veldic M, Caruncho HJ, Liu WS et al.: DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proc. NatlAcad. Sci. USA 101(1), 348-353 (2004). (Pubitemid 38084253)
26. Veldic M, Guidotti A, Maloku E et al.: In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc. NatlAcad. Sci. USA 102(6), 2152-2157 (2005). (Pubitemid 40262027)
27. Zhubi A, Veldic M, Puri N V et al.: An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schiz. Res. 111(1-3), 115-122 (2009).
28. Guidotti A, Dong E, Kundakovic M et al.: Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol. 30, 55-60 (2009).
29. 67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol. Pharmacol. 75(2), 342-354 (2009).
30. Noh JS, Sharma RP, Veldic M, S et al.: DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proc. NatlAcad. Sci. USA 102, 1749-1745 (2005).
31. Satta R, Maloku E, Zhubi A et al.: Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons. Proc. NatlAcad. Sci. USA 105, 16356-16361 (2008).
32. Abdolmaleky HM, Cheng KH, Russo A et al.: Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients, a preliminary report. Am. J. Med. Genet. BNeuropsychiatr. Genet. 134B(1), 60-66 (2005). (Pubitemid 40411111)
33. Poulter MO, Du L, Weaver IC et al.: GABAA receptor promoter hypermethylation in suicide brain, implications for the involvement of epigenetic processes. Biol. Psychiatry 64(8), 645-652 (2008).
34. Wyatt RJ, Termini BA, Davis JM: Biochemical and sleep studies of schizophrenia. A review of the literature 1960-1970. Schiz. Bull. 4, 10-44 (1971).
35. Tremolizzo L, Carboni G, Ruzicka WB et al.: An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. NatlAcad. Sci. USA 99(26), 17095-17100 (2002). (Pubitemid 36034104)
36. Tremolizzo L, Doueiri MS, Dong E et al.: Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol. Psychiatry 57(5). 500-509 (2005). (Pubitemid 40311985)
37. Guidotti A, Ruzicka W, Grayson DR et al.: 5-adenosyl methionine and DNA-methyltransferase-1 overexpression in psychosis. Neuroreport 18, 57-60 (2007). (Pubitemid 46183390)
38. Szyf M: DNA methylation and demethylation as targets for anticancer therapy. Biochemistry (Moscow) 70, 533-5449 (2005).
39. Dong E, Guidotti A, Grayson DR et al.: Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc-NatlAcad. Sci. USA 104(11), 4676-4681 (2007). (Pubitemid 47186284)
40. Dong E, Agis-Balboa C, Simonini MV et al.: Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc. NatlAcad. Sci. USA 102(35), 12578-12583(2005). (Pubitemid 41266401)
41. Dong E, Nelson M, Grayson DKet al.: Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. NatlAcad. Sci. USA 105(36), 13614-13619 (2008).
42. Keck Jr, PE, McElroy SL, Tugrul KC et al.: Valproate oral loading in the treatment of acute mama. J. Clin. Psychiatry 54(8), 305-308 (1993). (Pubitemid 23273947)
43. McElroy SL, Keck PE: Experience with valproate in affective disorders. In: Anticonvulsants in Psychiatry. Modigh K, Robak OH, Vestergaard P (Eds). Wrightson Biomedical Publishing Ltd, Hampshire, UK. 57-72 (1994).
44. Kusumakar V, Yatham LN, Haslam D et al.: Treatment of mania, mixed state, and rapid cycling. Can. J. Psychiatry 42 (Suppl. 2) 79S-86S (1997). (Pubitemid 27402415)
45. Stoll AL, Banov M, Kolbrener M et al.: Neurological factors predict a favorable valproate response in bipolar disorder. J. Clin. Psychopharmacol. 14, 311-313 (1994). (Pubitemid 24316927)
46. Puzynski S, Klociewicz L: Valproic acid amide as a prophylactic agent in the treatment of affective and schizoaffective disorders. Psychopharmacol. Bui. 20, 151-159 (1984). (Pubitemid 14128890)
47. Hayes SG: Long-term use of valproate in primary psychiatric disorders. J. Clin. Psychiatry 50, 35S-39S (1989).
48. Jacobsen FM: Low-dose valproate, a new treatment for cyclothymia, mild rapid-cycling disorders, and premenstrual syndrome. J. Clin. Psychiatry 54, 229-234 (1993). (Pubitemid 23213599)
49. Johannessen CU. Mechanisms of action of valproate, a commentary. Neurochem Int. 37(2-3), 103-110(2000).
50. Heninger GR. Charney DS, Sternberg DE: Lithium carbonate augmentation of antidepressant treatments. Arch. Gen. Psychiatry 40, 1335-1342 (1983).
51. Wassef A, Watson D, Morrison P: Neuroleptic-valproic acid combination in treatment of psychotic symptoms; a three-case report. J. Clin. Psychiatry 9, 45-48 (1989). (Pubitemid 19057165)
52. Sheard MH, Marini JL, Bridges CI: The effect of lithium on impulsive aggressive behavior in man. Am. J. Psychiatry 133, 1409-1413 (1976).
53. Luchins DL. Carbamazepine in violent nonepileptic schizophrenics. Psychopharmacol. Bull. 20, 569-571 (1984).
54. Morinigo A, Martin J, Gonzales S: Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside J. Clinic. Psych. 11, 199-207 (1989).
55. Detich N, Bovenzi V, Szyf M: Valproate induces replication-independent active DNA demethylation. J. Biol Chem. 278(30), 27586-27592 (2003). (Pubitemid 36899944)
56. Ma DK, Jang MH, Guo JU et al.: Neuronal activity-induced Gaddb promotes epigenetic DNA demethylation and adult neurogenesis. Science 323, 1074-1077 (2009).
57. Ooi SK, Bestor TH: The colorful history of active DNA demethylation. Cell 133(7), 1145-1148 (2008). (Pubitemid 351852922)
58. Roth BL, Sheffler DJ, Kroeze WK: Magic shotguns versus magic bullets: selectively nonselective drugs for mood disorders and schizophrenia. Nature Rev. Drug Discov. 3, 353-359 (2004). (Pubitemid 38499762)
59. Simonini M, Carmargo LM, Dong E et al.: The benzamide MS-275 is a potent long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl Acad. Sci. USA 103, 1587-1592 (2006). (Pubitemid 43191209)
60. Kelly DL, Conley RR, Feldman S et al.: Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiat. Q. 77, 81-95 (2006). (Pubitemid 43060798)
61. Wassef AA, Dott SG, Harris A et al.: Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J. Clin. Psychopharmacol. 20(3), 357-361 (2000). (Pubitemid 30318366)